Reach out and get your patients to read

Food Insecurity and the Dangers of Infant Formula Dilution

The indication is for patients 12 years and older hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

January 30th 2023

Weekly review: Key pediatric dermatology approvals and more

Demystifying Infant Formula

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

October 11th 2022

Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

Screen use and ways to protect pediatric eyesight

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN

FDA approves concizumab-mtci prophylaxis for hemophilia A and B

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the latest issue of Contemporary Pediatrics.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

The indication is for patients 12 years and older hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

January 30th 2023

Weekly review: Key pediatric dermatology approvals and more

Demystifying Infant Formula

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

October 11th 2022

Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

Screen use and ways to protect pediatric eyesight

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN